Free Trial
The Rate Lock Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 a Year
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$24.03
+3.4%		$23.37
$21.43
▼
$50.79
$756.27M0.73672,854 shs656,444 shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$4.05
+1.3%		$4.82
$3.79
▼
$9.94
$241.85M0.691.05 million shs2.70 million shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
+3.44%+2.26%+8.10%-32.10%-30.97%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
+1.25%0.00%-19.48%-20.59%-25.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$24.03
+3.4%		$23.37
$21.43
▼
$50.79
$756.27M0.73672,854 shs656,444 shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$4.05
+1.3%		$4.82
$3.79
▼
$9.94
$241.85M0.691.05 million shs2.70 million shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
+3.44%+2.26%+8.10%-32.10%-30.97%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
+1.25%0.00%-19.48%-20.59%-25.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.78
Moderate Buy$48.71102.72% Upside
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
2.44
Hold$13.08223.05% Upside

Current Analyst Ratings Breakdown

Latest VNDA and COLL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/15/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong Sell ➝ Strong-Buy
10/6/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold ➝ Strong Sell
10/6/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold ➝ Strong Sell
10/5/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$20.00
9/23/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$10.00
9/23/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$50.00
9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$45.00
9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$58.00 ➝ $49.00
9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$58.00 ➝ $49.00
9/9/2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$45.00
(Data available from 10/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$780.57M1.00$15.71 per share1.53$9.54 per share2.52
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$216.10M1.13N/AN/A$5.54 per share0.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$62.87M$1.2419.384.080.725.93%91.43%15.57%11/5/2026 (Estimated)
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$220.47M-$4.63N/AN/AN/A-119.87%-58.37%-36.21%N/A

Latest VNDA and COLL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.86N/AN/AN/A$216.03 millionN/A
10/28/2026Q3 2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.6820-$0.37+$0.3120-$0.37$69.20 million$69.82 million
8/6/2026Q2 2026
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.72$1.92+$0.20-$0.46$199.63 million$199.88 million
8/5/2026Q2 2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.5825-$1.04-$0.4575-$1.04$61.93 million$50.53 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.32
1.03
0.84
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
0.01
1.61
1.60

Institutional Ownership

CompanyInstitutional Ownership
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
88.14%

Insider Ownership

CompanyInsider Ownership
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
1.85%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
10.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
42332.56 million31.95 millionOptionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
53360.46 million53.99 millionOptionable

Recent News About These Companies

Vanda targets full-year 2026 total revenues greater than $240M as BYSANTI launch nears Q4
October 29 at 8:05 AM  |  seekingalpha.comhttps://seekingalpha.com/news/4659893-vanda-targets-full-year-2026-total-revenues-greater-than-240m-as-bysanti-launch-nears-q4
Vanda (VNDA) Q3 2026 Earnings Call Transcript
October 29 at 8:05 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vanda-vnda-q3-2026-earnings-054403129.html
Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call Transcript
October 29 at 4:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4959096-vanda-pharmaceuticals-inc-vnda-q3-2026-earnings-call-transcript
Vanda Pharmaceuticals Inc. reports third quarter 2026 financial results
October 29 at 1:06 AM  |  msn.comhttps://www.msn.com/en-us/money/other/vanda-pharmaceuticals-inc-reports-third-quarter-2026-financial-results/ar-AA2ghRcs
Vanda Pharmaceuticals Q3 Earnings Call Highlights
October 28 at 8:03 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/transcript-vanda-pharmaceuticals-q3-earnings-call-highlights-2026-10-28/
Vanda Pharmaceuticals (NASDAQ:VNDA) Announces Earnings Results, Beats Estimates By $0.31 EPS
October 28 at 7:10 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/earnings-vanda-pharmaceuticals-nasdaq-vnda-announces-earnings-results-beats-estimates-by-031-eps-2026-10-28/
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates
October 28 at 6:20 PM  |  zacks.comhttps://www.zacks.com/stock/news/3017688/vanda-pharmaceuticals-vnda-reports-q3-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-3017688
Vanda Pharmaceuticals (VNDA) Releases Q3 2026 Earnings: Revenue Plunges and Loss Widens
October 28 at 4:50 PM  |  quiverquant.comQ
Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results
October 28 at 4:01 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-third-quarter-2026-financial-results-302922677.html
Vanda Pharmaceuticals Announces Encouraging Data From NEREUS Phase 3 Study
October 28 at 9:07 AM  |  rttnews.comhttps://www.rttnews.com/3703496/vanda-pharmaceuticals-announces-encouraging-data-from-nereus-phase-3-study.aspx
Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes
October 27 at 2:31 PM  |  benzinga.comhttps://www.benzinga.com/markets/biotech/26/10/62632019/vanda-pharmaceuticals-targets-major-glp-1-market-challenge-with-positive-trial-outcomes
Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes
October 27 at 2:13 PM  |  benzinga.comhttps://www.benzinga.com/markets/biotech/26/10/62632019/vanda-pharmaceuticals-targets-major-glp-1-market-challenge-with-positive-trial-outcomes?utm_source=snapi
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
October 27 at 6:50 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-positive-results-from-study-3601-of-nereus-tradipitant-for-prevention-of-glp-1induced-vomiting-302920054.html
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock Has Consensus Price Target of $13.08 According to Brokerages
October 27 at 4:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-vanda-pharmaceuticals-inc-nasdaq-vnda-stock-has-consensus-price-target-of-1308-according-to-brokerages-2026-10-27/
Vanda Pharmaceuticals (VNDA) Set to Post Earnings on Wednesday
October 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31148243
Vanda Pharmaceuticals (VNDA) Projected to Release Quarterly Earnings on Wednesday
October 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-vanda-pharmaceuticals-vnda-projected-to-release-quarterly-earnings-on-wednesday-2026-10-23/
Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026
October 21, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-third-quarter-2026-financial-results-on-october-28-2026-302916061.html
Vanda puts VQW-765 on hold: Vanda Pharmaceuticals stock costs EUR 3.64
October 21, 2026  |  ad-hoc-news.deA
Vanda puts VQW-765 on hold: what it means for Vanda Pharmaceuticals stock
October 18, 2026  |  ad-hoc-news.deA
Vanda Pharmaceuticals: Cash Is Running Out Faster Than The Launches
October 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4954594-vanda-pharmaceuticals-cash-is-running-out-faster-than-the-launches?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
October 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-10/69842490-vanda-pharmaceuticals-inc-vanda-pharmaceuticals-provides-update-on-vqw-765-clinical-development-program-008.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$24.03 +0.80 (+3.44%)
Closing price 10/29/2026 04:00 PM Eastern
Extended Trading
$24.02 -0.02 (-0.06%)
As of 10/29/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$4.05 +0.05 (+1.25%)
Closing price 10/29/2026 04:00 PM Eastern
Extended Trading
$4.01 -0.04 (-0.96%)
As of 10/29/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas